Gland B2B Business Model and Growth Strategy slide image

Gland B2B Business Model and Growth Strategy

Injectables: One of the Largest and Fastest Growing Segment 19 1 Injectable formulations is the fastest growing segment in global pharmaceuticals, recording a 2014-2019 CAGR of 10.1% vs overall pharma market at 5.8% Growth Opportunity Global generic injectables market is estimated at c.US$131bn growing at a 2014-19 CAGR of c. 8% US the largest market (i.e. c. 33-34% of market) is expected to grow at a c.16% CAGR from 2019-2024E c.US$61.3bn in injectable brand sales expected to lose patent protection between 2020-24 (vs c. US$33bn in sales which lost patent protection lost between 2014-19) 2 Growth Drivers for Injectables Rising prevalence of chronic diseases Convenience and benefits of New Drug Delivery Systems ("NDDS") New market opportunities Drug shortages in the US – from 2014 to 2019 c. 40-60% of the shortages have been in injectables space 3 Market Entry Barriers High capital investments Manufacturing complexities to meet stringent quality standards High level of compliance and regulatory requirements Consolidation trend expected to favour established players Source: IQVIA Report. GLAND
View entire presentation